Greenwich LifeSciences stock gains on GP2 update (GLSI)

Last updated: January 22, 2025 8:11 pm

By MT HANNACH

Add a Comment

0 Min Read

Disclosure: This website may contain affiliate links, which means I may earn a commission if you click on the link and make a purchase. I only recommend products or services that I personally use and believe will add value to my readers. Your support is appreciated!

Greenwich Life Sciences (NASDAQ:GLSI) is trading higher on Wednesday after the immunotherapy developer provided an update on the commercial manufacturing of its lead candidate GP2, which is currently in a late-stage trial called FLAMINGO-01 for breast cancer. breast.

Noting that data on commercial manufacturing also